Roles of Cytochrome P450 Enzymes in Pharmacology and Toxicology: Past, Present, and Future

Overview

Journal Adv Pharmacol

Specialty Pharmacology

Date 2022 Aug 11

PMID 35953152

Authors

F Peter Guengerich

Affiliations

Soon will be listed here.

Abstract

The development of the cytochrome P450 (P450) field has been remarkable in the areas of pharmacology and toxicology, particularly in drug development. Today it is possible to use the knowledge base and relatively straightforward assays to make intelligent predictions about drug disposition prior to human dosing. Much is known about the structures, regulation, chemistry of catalysis, and the substrate and inhibitor specificity of human P450s. Many aspects of drug-drug interactions and side effects can be understood in terms of P450s. This knowledge has also been useful in pharmacy practice, as well as in the pharmaceutical industry and medical practice. However, there are still basic and practical questions to address regarding P450s and their roles in pharmacology and toxicology. Another aspect is the discovery of drugs that inhibit P450 to treat diseases.

Citing Articles

Laying the groundwork: Exploring pesticide exposure and genetic factors in south-eastern Brazilian farmers.

Meira D, Da Gama Kohls V, Casotti M, Louro L, Santana G, Santos Louro T Curr Res Toxicol. 2025; 8:100215.

PMID: 39895912 PMC: 11783379. DOI: 10.1016/j.crtox.2025.100215.

Human CYP2D6 varies across the estrous cycle in brains of transgenic mice altering drug response.

Miksys S, McDonald C, Baghai Wadji F, Gonzalez F, Tyndale R Prog Neuropsychopharmacol Biol Psychiatry. 2024; 135:111108.

PMID: 39069248 PMC: 11402587. DOI: 10.1016/j.pnpbp.2024.111108.

Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.

Guengerich F Pharmacol Rev. 2024; 76(6):1104-1132.

PMID: 39054072 PMC: 11549934. DOI: 10.1124/pharmrev.124.001173.

Steroidogenic cytochrome P450 enzymes as drug target.

Kim C, Jeong E, Lee Y, Kim D Toxicol Res. 2024; 40(3):325-333.

PMID: 38911541 PMC: 11187042. DOI: 10.1007/s43188-024-00237-0.

Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.

Peixoto C, Joncour A, Temal-Laib T, Tirera A, Dos Santos A, Jary H J Med Chem. 2024; 67(7):5233-5258.

PMID: 38552030 PMC: 11017251. DOI: 10.1021/acs.jmedchem.3c02246.

References

Williams P, Cosme J, Sridhar V, Johnson E, McRee D . Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell. 2000; 5(1):121-31. DOI: 10.1016/s1097-2765(00)80408-6. View

Hedegaard J, GUNSALUS I . Mixed function oxidation. IV. An induced methylene hydroxylase in camphor oxidation. J Biol Chem. 1965; 240(10):4038-43. View

Gonzalez F, Kimura S . Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys. 2002; 409(1):153-8. DOI: 10.1016/s0003-9861(02)00364-8. View

Wang C, Pallan P, Zhang W, Lei L, Yoshimoto F, Waterman M . Functional analysis of human cytochrome P450 21A2 variants involved in congenital adrenal hyperplasia. J Biol Chem. 2017; 292(26):10767-10778. PMC: 5491764. DOI: 10.1074/jbc.M117.792465. View

Dannan G, Guengerich F, Kaminsky L, Aust S . Regulation of cytochrome P-450. Immunochemical quantitation of eight isozymes in liver microsomes of rats treated with polybrominated biphenyl congeners. J Biol Chem. 1983; 258(2):1282-8. View

McLean K, Dunford A, Neeli R, Driscoll M, Munro A . Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems. Arch Biochem Biophys. 2007; 464(2):228-40. DOI: 10.1016/j.abb.2007.03.026. View

Eng H, Tseng E, Cerny M, Goosen T, Obach R . Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for.... Drug Metab Dispos. 2021; 49(6):442-450. DOI: 10.1124/dmd.121.000356. View

Yasuda K, Nishikawa M, Okamoto K, Horibe K, Mano H, Yamaguchi M . Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by CYP24A1 and CYP3A using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. J Biol Chem. 2021; 296:100668. PMC: 8134072. DOI: 10.1016/j.jbc.2021.100668. View

Reddish M, Guengerich F . Human cytochrome P450 11B2 produces aldosterone by a processive mechanism due to the lactol form of the intermediate 18-hydroxycorticosterone. J Biol Chem. 2019; 294(35):12975-12991. PMC: 6721951. DOI: 10.1074/jbc.RA119.009830. View

10.

Rosenberger L, von Essen C, Khutia A, Kuhn C, Urbahns K, Georgi K . Crystalline Sponges as a Sensitive and Fast Method for Metabolite Identification: Application to Gemfibrozil and its Phase I and II Metabolites. Drug Metab Dispos. 2020; 48(7):587-593. DOI: 10.1124/dmd.120.091140. View

11.

Chun Y, Kim S, Kim D, Lee S, Guengerich F . A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 2001; 61(22):8164-70. View

12.

Isin E, Guengerich F . Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4. J Biol Chem. 2007; 282(9):6863-74. DOI: 10.1074/jbc.M610346200. View

13.

Guengerich F, Yoshimoto F . Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions. Chem Rev. 2018; 118(14):6573-6655. PMC: 6339258. DOI: 10.1021/acs.chemrev.8b00031. View

14.

Shinkyo R, Guengerich F . Inhibition of human cytochrome P450 3A4 by cholesterol. J Biol Chem. 2011; 286(21):18426-33. PMC: 3099659. DOI: 10.1074/jbc.M111.240457. View

15.

Yun C, Kim K, Calcutt M, Guengerich F . Kinetic analysis of oxidation of coumarins by human cytochrome P450 2A6. J Biol Chem. 2005; 280(13):12279-91. DOI: 10.1074/jbc.M411019200. View

16.

Wiwi C, Waxman D . Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2. J Biol Chem. 2004; 280(5):3259-68. DOI: 10.1074/jbc.M409294200. View

17.

MANNERING G, Renton K, el Azhary R, Deloria L . Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems. Ann N Y Acad Sci. 1980; 350:314-31. DOI: 10.1111/j.1749-6632.1980.tb20631.x. View

18.

Takakusa H, Masumoto H, Yukinaga H, Makino C, Nakayama S, Okazaki O . Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity. Drug Metab Dispos. 2008; 36(9):1770-9. DOI: 10.1124/dmd.108.021725. View

19.

Ingelman-Sundberg M, Zhong X, Hankinson O, Beedanagari S, Yu A, Peng L . Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos. 2013; 41(10):1725-31. PMC: 3781370. DOI: 10.1124/dmd.113.053157. View

20.

Lang D, Radtke M, Bairlein M . Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans. Chem Res Toxicol. 2019; 32(6):1115-1122. DOI: 10.1021/acs.chemrestox.8b00413. View